Histopathology and antibody screening of Hutchinson Gilford progeria syndrome mouse model DNA editing therapeutic preclinical trial samples.

The National Institutes of Health (NIH) is seeking a contractor to perform histopathology and antibody screening of mouse model DNA editing therapeutic preclinical trial samples for Hutchinson Gilford progeria syndrome. The contractor will be responsible for processing and analyzing tissue samples from 60 mice, including histopathology staining and AAV9 antibody screening. The study aims to demonstrate the efficacy and non-toxicity of the DNA editing therapeutic. The contractor will be required to follow Good Laboratory Practice (GLP) guidelines and provide detailed reports of their findings. Some key aspects of the job include: • Processing and analyzing tissue samples from 60 mice • Performing histopathology staining, including hematoxylin and eosin, Movat's pentachrome, and other stains • Conducting AAV9 antibody screening using a proprietary assay • Providing detailed reports of findings, including GLP-compliant documentation • Returning all histopathology slides and tissue samples to the NIH at the completion of the project